|
|
| (182 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | + | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| | + | *'''[[Clinical guidelines and advice]]''' |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Respiration mgmt]]''' |
| | + | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | + | |
| | + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | *
| |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32311462|t=2020. On the molecular determinants of the SARS-CoV-2 attack |pdf=|usr=}}
| |
| − | {{tp|p=32129843|t=ä. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients |pdf=|usr=}}
| |
| − | {{tp|p=32129842|t=ä. A glimpse into the origins of genetic diversity in SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32229288|t=ä. Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32271376|t=ä. Factors associated with prolonged viral RNA shedding in patients with COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | + | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
| |
| − | {{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}}
| |
| − | {{tp|p=32161940|t=ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32280952|t=ä. Good IgA bad IgG in SARS-CoV-2 infection?|pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 34: |
Zeile 39: |
| | | | |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Pathobiology]]''' |
| − | * | + | |
| | + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | *'''[[Early symptoms]]''' | | *'''[[Early symptoms]]''' |
| | + | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32358954|t=ä. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing |pdf=|usr=}}
| |
| − | {{tp|p=32361747|t=ä. COVID-19, superinfections and antimicrobial development: What can we expect?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| − | {{tp|p=32173725|t=ä. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32161968|t=ä. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias |pdf=|usr=}}
| |
| − | {{tp|p=32271373|t=ä. Predictors of refractory Coronavirus disease (COVID-19) pneumonia |pdf=|usr=}}
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32250159|t=2020. Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32178975|t=ä. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32371557|t=2020. SARS-CoV-2 and myocardial injury: Few answers, many questions |pdf=|usr=}}
| + | |
| − | {{tp|p=32331780|t=ä. COVID-19-related cardiac involvement and potential implications for cardiothoracic imaging |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32357210|t=ä. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32215618|t=ä. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| − | *'''[[Kidney, urology]]== | + | *'''[[The morbid survivor]]''' |
| − | *
| + | |
| − | *'''[[Pathobiology]]'''
| + | |
| | | | |
| − | *'''[[Disease Models]]''' | + | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32215622|t=ä. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | *
| |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| − | {{tp|p=32327229|t=2020. CT characteristics of patients infected with 2019 novel coronavirus: association with clinical type |pdf=|usr=}}
| |
| − | {{tp|p=32331781|t=ä. Ultrasound in COVID-19: a timeline of ultrasound findings in relation to CT |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32360444|t=ä. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP) |pdf=|usr=}}
| |
| − | {{tp|p=32216962|t=2020. An update on COVID-19 for the radiologist - A British society of Thoracic Imaging statement |pdf=|usr=}}
| |
| − | {{tp|p=32344166|t=ä. COVID-19 pandemic?a focused review for clinicians |pdf=|usr=}}
| |
| − | {{tp|p=32216961|t=2020. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area |pdf=|usr=}}
| |
| − | {{tp|p=32321645|t=ä. The continuing evolution of COVID-19 imaging pathways in the UK: a British Society of Thoracic Imaging expert reference group update |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Respiration mgmt]]'''
| |
| − | {{tp|p=32371555|t=2020. Utility of extracorporeal membrane oxygenation in COVID-19 |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32304745|t=ä. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32161990|t=ä. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China |pdf=|usr=}}
| |
| − | {{tp|p=32328736|t=ä. No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32147731|t=ä. Diagnosis and Management of First Case of COVID-19 in Canada: Lessons applied from SARS |pdf=|usr=}}
| |
| − | {{tp|p=32227197|t=ä. A Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARS CoV2 in the United States |pdf=|usr=}}
| |
| − | {{tp|p=32211789|t=ä. The first locally acquired novel case of 2019-nCoV infection in a healthcare worker in the Paris area |pdf=|usr=}}
| |
| − | {{tp|p=32240285|t=ä. First Mildly Ill, Non-Hospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States ? Maricopa County, Arizona, 2020 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32251842|t=ä. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital |pdf=|usr=}}
| |
| − | {{tp|p=32359867|t=ä. Impact of gender on extent of lung injury in COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Registries]]''' |
| | | | |
| | | | |
| − | *
| |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| | + | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32344167|t=ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study |pdf=|usr=}}
| |
| − | {{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32306288|t=ä. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| − | *'''[[Biophysics of aerosols]]'''
| |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32241022|t=ä. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32297915|t=ä. Comment of the potential risks of sexual and vertical transmission of Covid-19 infection |pdf=|usr=}}
| + | |
| | + | *'''[[Biophysics of aerosols]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32315026|t=ä. Responding to the COVID-19 outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems |pdf=|usr=}}
| + | |
| − | {{tp|p=32166318|t=ä. Protecting Health Care Workers during the COVID-19 Coronavirus Outbreak ?Lessons from Taiwan s SARS response |pdf=|usr=}}
| + | |
| − | *
| + | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32371561|t=2020. Pulmonary function testing precautions in a time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32371560|t=2020. PAP therapy increases the risk of transmission of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32252508|t=2020. Sharing Our Experience of Operating an Endoscopy Unit in the Midst of a COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32371164|t=ä. RECOMMENDATIONS FOR ESSENTIAL ESOPHAGEAL PHYSIOLOGICTESTING DURING THE COVID-19 PANDEMIC |pdf=|usr=}}
| |
| − | {{tp|p=32304737|t=ä. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32166310|t=ä. A Novel Approach for a Novel Pathogen: using a home assessment team to evaluate patients for 2019 novel coronavirus (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32278082|t=ä. Challenges and issues about organising a hospital to respond to the COVID-19 outbreak: experience from a French reference centre |pdf=|usr=}}
| |
| − | {{tp|p=32330569|t=ä. Clinical microbiology laboratory adaptation to COVID-19 emergency: experience at a large teaching hospital in Rome, Italy |pdf=|usr=}}
| |
| − | {{tp|p=32312609|t=ä. Full Spectrum of Cancer Patients in SARS-CoV-2 Infection Still Being Described |pdf=|usr=}}
| |
| − | {{tp|p=32299723|t=ä. Considerations for the Treatment of Oesophageal Cancer With Radiotherapy During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32362444|t=ä. Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32359847|t=ä. Challenges and Consequences of COVID-19 in the Management of Anorectal Cancer: Coming Together Through Social Distancing |pdf=|usr=}}
| |
| − | {{tp|p=32354668|t=ä. Effect of COVID-19 pandemic on cancer clinician decision making: Known knowns and known unknowns |pdf=|usr=}}
| |
| − | {{tp|p=32359846|t=2020. Managing the COVID-19 Pandemic as a National Radiation Oncology Centre in Singapore |pdf=|usr=}}
| |
| − | {{tp|p=32246280|t=ä. Health services provision of 48 public tertiary dental hospitals during the COVID-19 epidemic in China |pdf=|usr=}}
| |
| − | {{tp|p=32078048|t=ä. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis |pdf=|usr=}}
| |
| − | {{tp|p=32265036|t=2020. A British Society of Thoracic Imaging statement: considerations in designing local imaging diagnostic algorithms for the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32291080|t=ä. Planning and coordination of the radiological response to the coronavirus disease 2019 (COVID-19) pandemic: the Singapore experience |pdf=|usr=}}
| |
| − | {{tp|p=32299617|t=2020. Respirators and surgical facemasks for COVID-19: implications for MRI |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32246142|t=ä. Care for the psychological status of frontline medical staff fighting against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32339218|t=ä. Working schedule, sleep quality and susceptibility to COVID-19 in healthcare workers |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32371559|t=2020. Helping children cope with the COVID-19 pandemic |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Educational aspects of the status hygienicus]]''' | | *'''[[Educational aspects of the status hygienicus]]''' |
| − | *
| + | ---- |
| | + | |
| | + | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| | + | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | + | *'''[[Epidemiology]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| − | {{tp|p=32311512|t=ä. Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32266381|t=ä. PCR Assays Turned Positive in 25 Discharged COVID-19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32302000|t=ä. The duration of viral shedding of discharged patients with severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32360448|t=ä. SARS-CoV-2 positivity in a discharged COVID-19 patient: A Case report |pdf=|usr=}}
| |
| − | {{tp|p=32304746|t=ä. A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Epidemiology]]'''
| |
| − | {{tp|p=32344169|t=ä. A cluster of COVID-19 cases in a small Italian town: a successful example of contact tracing and swab collection |pdf=|usr=}}
| |
| − | {{tp|p=32344168|t=ä. Early diagnosis and rapid isolation: response to COVID-19 outbreak in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32354669|t=ä. COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]'''
| |
| − | {{tp|p=32246996|t=ä. The SARS-CoV-2 epidemic: how the Italian public is being informed |pdf=|usr=}}
| |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | + | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | + | |
| | + | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| | + | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | + | ---- |
| | + | |
| | + | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | *'''[[Current state of coviki.org]]'''
| |
| − | *[[PubMed selected papers unsorted to be listed in contents topics]]
| |
| − | *[[coviki state of development]]
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32296817|t=ä. Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials |pdf=|usr=}} | + | |
| − | {{tp|p=32360446|t=2020. COVID-19: don t neglect antimicrobial stewardship principles!|pdf=|usr=}} | + | |
| − | {{tp|p=32058086|t=2020. Novel coronavirus: how things are in Wuhan |pdf=|usr=}}
| + | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | + | *'''[[from the ads]]''' |
| | + | |
| | + | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
